Potential use of genetically modified pigs as organ donors for transplantation into humans

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 12, 1999, Pages 1020-1025

  Logan, John S ^a,b   Sharma, Ajay ^a  

^a Nextran   (United States)

^b NONE   (United States)

Author keywords

Complement; Hyperacute rejection; Transgenic; Xenotransplantation

Indexed keywords

REGULATOR PROTEIN;

COMPLEMENT ACTIVATION; CONFERENCE PAPER; GENETIC ENGINEERING; GRAFT REJECTION; HUMAN; NONHUMAN; ORGAN DONOR; SWINE; TRANSGENIC ANIMAL; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; HUMANS; SWINE; TISSUE DONORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033431784     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.03185.x     Document Type: Conference Paper

References (48)

1. 1. United Network for organ Sharing 1999 (on-line). http://www.unos.org
2. 2. Evans R. Executive Summary: The National Cooperative Transplantation Study, BHARC-100-91-020. Battelle-Seattle Research Center, Seattle, WA. 1991.
3. 3. Evans RW, Orians CE, Ascher NL. The potential supply of organ donors: An assessment of the efficiency of organ procurement efforts in the United States. JAMA 1992; 267: 239-46.
4. 4. Department of Health and Human Services (USA)/Food and Drug Administration. Guidance for Industry. Public Health Issues Posed by the Use of Non-Human Primate Xenografts in Humans. Government Printing Office, Washington, DC. 1999.
5. 5. Cooper DKC, Human PA, Lexer G et al. Effects of cyclosporine and antibody adsorption on pig cardiac xenograft survival in the baboon. J. Heart Transplant. 1988; 7: 238-46.
6. 6. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52: 214-20.
7. 7. Galili U, Matta KL. Inhibition of anti-gal IgG binding to porcine endothelial cells by synthetic oligosaccharides. Transplantation 1996; 62: 256-62.
8. 8. Good H, Cooper DKC, Malcolm AJK et al. Identification of carbohydrate structures which bind human anti-porcine antibodies: Implications for discordant grafting in man. Transplant. Proc. 1992; 24: 559-62.
9. 9. LaVecchio JA, Dunne AD, Edge ASB. Enzymatic removal of alphagalactosyl epitopes from porcine endothelial cells diminishes the cytotoxic effect of natural antibodies. Transplantation 1995; 60: 841-7.
10. 10. Lin SS, Kooyman DL, Daniels LJ et al. The role of natural antiGalα1-3Gal antibodies in hyperacute rejection of pig-to-baboon cardiac xenotransplants. Transplant. Immunol. 1997; 5: 212-18.
11. 11. Neethling FA, Koren E, Ye Y et al. Protection of pig kidney (PK15) cells from the cytotoxic effect of anti-pig antibodies by α-galactosyl oligosaccharides. Transplantation 1994; 57: 959-63.
12. 12. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC. Anti-pig IgM antibodies in human serum react predominantly with Galα(1,3)Gal epitopes. Proc. Natl Acad. Sci. USA 1993; 90: 11 391-5.
13. 13. Taniguchi S, Neethling FA, Korchagina EY et al. In vivo immunoadsorption of antipig antibodies in baboons using a specific Galα 1-3Gal column. Transplantation 1998; 62: 1379-84.
14. 14. Watier H, Guillaumin J-M, Piller F et al. Removal of terminal α-galactosyl residues from xenogeneic porcine endothelial cells. Transplantation 1996; 62: 105-13.
15. 15. Collins BH, Parker W, Platt JL. Characterization of porcine endothelial cell determinants recognized by human natural antibodies. Xenotransplantation 1994; 1: 36-46.
16. 16. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the natural anti-Gal antibody and the Galα 1-3Gal epitope in primates. Proc. Natl Acad. Sci. USA 1987; 84: 1369-73.
17. 17. Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. Man, apes and old world monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J. Biol. Chem. 1988; 263: 17 755-62.
18. 18. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect. Immun. 1988; 56: 1730-7.
19. 19. Parker W, Lundberg-Swanson KL, Holzknecht ZE et al. Isohemagglutinins and xenoreactive antibodies are members of a distinct family of natural antibodies. Hum. Immunol. 1996; 45: 94-104.
20. 20. Atkinson JP, Fairies T. Separation of self from non-self in the complement system. Immunol. Today 1987; 8: 212-15.
21. 21. Miyagawa S, Hirose H, Shirakura R et al. The mechanism of discordant xenograft rejection. Transplantation 1988; 46: 825-30.
22. 22. Platt JL, Vercellotti GM, Dalmasso AP et al. Transplantation of discordant xenografts: A review of progress. Immunol. Today 1990; 11: 450-7.
23. 23. Hammer RE, Pursel VG, Rexroad Jr CE et al. Production of transgenic rabbits, sheep and pigs by microinjection. Nature 1985; 315: 680-3.
24. 24. Logan JS, Martin M. Transgenic swine as a recombinant production system for human hemoglobin. Methods Enzymol. 1993; 231: 435-45.
25. 25. Milot E, Strouboulis J, Trimborn T et al. Heterochromatin effects on the frequency and duration of LCR-mediatcd gene transcription. Cell 1996; 87: 105-14.
26. 26. Kooyman DL, Byrne GW, McClellan S et al. In vivo transfer of GPI linked complement restriction factors from erythrocytes to the endothelium. Science 1995; 269: 89-92.
27. 27. McCurry KR, Kooyman DL, Alvarado CG et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med. 1995; 1: 423-7.
28. 28. Byrne GW, McCurry KR, Martin MJ, McClellan SM, Platt JL, Logan JS. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63: 149-55.
29. 29. Oldham ER, Velardo MA, Platt JL, Logan JS, Diamond L. High-level tissue specific expression of human CD59, MCP, and DAF proteins from genomic clones in transgenic mice. Transplant. Proc. 1996; 28: 693.
30. 30. Lawson JH, Diamond LE, Martin MJ et al. Expression of human complement regulatory proteins CD59 and decay accelerating factor (DAF) prolongs graft survival and physiological function in pig-to-baboon kidney transplantation. In: Proceedings of the Fourth International Congress for Xenotransplantation, 7-11 September 1997, Nantes, France. 1997; Abstract 047.
31. 31. Diamond LE, Martin MJ, Adams D et al. Transgenic pig heart and kidneys expressing human CD59, CD55, or CD46 are protected from hyperacute rejection upon transplantation into baboons. In: Proceedings of the Fourth International Congress for Xenotransplantation, 7-11 September 1997, Nantes, France. 1997; Abstract 0185.
32. 32. Waterworth PD, Cozzi E, Tolan MJ et al. Pig-to-primate cardiac xenotransplantation and cyclophosphamide therapy. Transplant. Proc. 1997; 29: 899-900.
33. 33. Lin S, Weidner BC, Byrne GW et al. The role of antibodies in acute vascular rejection of pig-to-haboon cardiac transplants. J. Clin. Invest. 1998; 101: 1745-56.
34. 34. McCurry KR, Parker W, Cotterell AH et al. Humoral responses to pig-to-baboon cardiac transplantation: Implications for the pathogenesis and treatment of acute vascular rejection and for accommodation. Hum. Immunol. 1997; 58: 91-105.
35. 35. Collins BH, Chari RS, Magee JC et al. Mechanisms of injury in porcine livers perfused with blood of patients with fulminant hepatic failure. Transplantation 1994; 58: 1162-71.
36. 36. Kozlowski T, Monroy R, Xu Y et al. Anti-Galα 1-3Gal antibody response to porcine bone marrow in unmodified baboons and baboons conditioned for tolerance induction. Transplantation 1998; 66: 176-82.
37. 37. Galili U, Latemple DC, Walgenbach AW, Stone KR. Porcine and bovine cartilage transplants in cynomolgus monkey. Transplantation 1997; 63: 646-51.
38. 38. Susulic VS, Frederich RC, Lawitts J et al. Targeted disruption of the beta 3-adrenergic receptor gene. J. Biol. Chem. 1995; 270: 29483-92.
39. 39. Thall AD, Maly P, Lowe JB. Oocyte Gal alpha, 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J. Biol. Chem. 1995; 270: 21 437-40.
40. 40. Tearle RG, Tange MJ, Zannettino ZL et al. The α-1,3-galactosyltransferase knockout mouse. Transplantation 1996; 61: 13-19.
41. 41 Baguisi A, Behboddi E, Melican DT et al. Production of goats by somatic cell nuclear transfer. Nature Biotech. 1999; 17: 456-61.
42. 42. Campbell KHS, McWhir J, Ritchie WA, Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. Nature 1998; 380: 64-6.
43. 43. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KHS. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385: 810-13.
44. 44. Cibelli JB, Stice SL, Golueke PJ et at. Cloned transgenic calves produced from nonquiescent fetal fibroblasts. Science 1998; 280: 1256-8.
45. 45. Wakayama T, Perry ACF, Zuccotti M, Johnson KR, Yanagimachi R. Full-term development of mice from enucleated oocytes injected with cumulus cells nuclei. Nature 1998; 394: 369-74.
46. 46. Osman N, Mckenzie IFC, Ostenried K, Ioannou YA, Desnick RJ, Sandrin MS. Combined transgenic expression of α-galactosidase and α 1,2-fucosyltransferase leads to optimal reduction in the major xenoepitope Galα(1,3)Gal. Proc. Natl Acad. Sci. USA 1997; 94: 14677-82.
47. 47. Sandrin MS, Fodor WL, Mouhtouris E et al. Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nature Med. 1995;1: 1261-7.
48. 48. Sharma A, Okabe J, Birch P et al. Reduction in the level of Gal(α1,3)Gal in transgenic mice and pigs by the expression of an α(1,2)fucosyltransferase. Proc. Natl Acad. Sci. USA 1996; 93: 7190-5.